eClinical Technology and Industy News

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers

-Additional presentations to detail clinical data from Tern’s extensive pipeline, including TERN-101 and TERN-201

Excerpt from the Press Release:

FOSTER CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced that results from clinical trials of TERN-501, TERN-101 and TERN-201 will be highlighted in several presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC) 2022, taking place June 22-26 in London, United Kingdom. The Company’s presentations will include four posters and one oral presentation.

The oral presentation titled “Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study,” will be delivered by Cara Nelson, Ph.D., senior director of clinical pharmacology at Terns, on Saturday, June 25 at 6:15 p.m. BT. This presentation will highlight results from the multiple ascending dose (MAD) cohort of the Phase 1 clinical trial of TERN-501 in healthy volunteers with mildly elevated low-density lipoprotein cholesterol (LDL-c). 3, 6 and 10 mg of TERN-501 administered for 14 days was overall safe and well-tolerated with no study drug discontinuations and significant, dose-dependent increases in sex hormone binding globulin, a marker of THR-β target engagement in the liver that has been associated with liver fat content reductions and histopathologic improvements in THR-β treated NASH patients. This study supports further investigation of TERN-501 for NASH treatment alone or in combination with other agents.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives